ShareValue scores for FRE.XETRA: Valuation 67, Quality 38, Growth 48, Health 43.

Fresenius SE & Co. KGaA logo

FRE.XETRA
XETRA

Fresenius SE & Co. KGaA

€46.68(+0.06%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

7% to 18%
Valuation
67
Fair Value
Price vs Value
Quality
38
Weak
Business Strength
Growth
48
Moderate
Revenue & Earnings
Health
43
Moderate
Financial Stability
Momentum
23
Bearish
Price Trend

Company Details

About

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients in North America, Europe, the Asia-Pacific, Latin America, and Africa. It operates through Fresenius Kabi and Fresenius Helios segments. The Fresenius Kabi segment offers products for therapy and care of critically and chronically ill patients, including biopharmaceuticals, clinical nutrition, MedTech products, intravenously administered generic drugs, and IV fluids. It also provides biosimilar drugs; enteral and parenteral nutrition products; and medical technologies that include disposables, infusions pumps, apheresis machines, cell therapy devices, and other products. The Fresenius Helios segment operates hospitals, medical care centers, occupational health centers, prevention centers, and outpatient health centers, as well as provision of medical diagnostics. The company has a strategic collaboration with SAP SE and Avelios Medical GmbH for the development of a cloud-native, modular hospital information system that enables digitalization of clinical and administrative processes with AI integration. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is based in Bad Homburg vor der Höhe, Germany.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026